MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
P/B ratio for MediciNova, Inc. (MNOV)
P/B ratio as of 2023: 1.18
According to MediciNova, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.18. At the end of 2022 the company had a P/B ratio of 1.43.
P/B ratio history for MediciNova, Inc. from 2001 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.18 |
| 2022 | 1.43 |
| 2021 | 1.56 |
| 2020 | 3.28 |
| 2019 | 3.88 |
| 2018 | 4.60 |
| 2017 | 5.88 |
| 2016 | 5.76 |
| 2015 | 2.88 |
| 2014 | 3.32 |
| 2013 | 1.74 |
| 2012 | 1.90 |
| 2011 | 1.07 |
| 2010 | 2.37 |
| 2009 | 2.13 |
| 2008 | 0.40 |
| 2007 | 0.81 |
| 2006 | 1.33 |
| 2005 | 0.72 |
| 2004 | 0.07 |
| 2003 | 0.12 |
| 2002 | 0.49 |
| 2001 | 0.07 |